On November 24, 2017 LIDDS reported that it has started four internal projects that focus on assessing the feasibility of using the NanoZolid drug delivery technology for local or intratumoral immunotherapy (Press release, Lidds, NOV 24, 2017, View Source [SID1234555922]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These feasibility studies will investigate if four different immunomodulatory agents can be formulated with the NanoZolid drug delivery technology. The studies include biophysical and pharmacological characterization as well as studies in relevant disease models. The objective is to demonstrate that the NanoZolid drug delivery technology can be leveraged to develop novel immunotherapies that can act locally or intratumorally. A locally delivered immunotherapy has the potential to act either as a monotherapy or in combination with systemic immunotherapies e.g. checkpoint inhibitors. A successful combination treatment could significantly increase the response rates and efficacy rates of current immunotherapies.

Results from these preclinical feasibility studies are expected in the first and second quarter of 2018.

Immunotherapy for the treatment of cancer aims to activate and utilize the body’s own immune system to recognize and attack tumors and cancer cells and is today the fastest growing and most promising area of cancer research.